Dechra Pharmaceuticals logo

DPH - Dechra Pharmaceuticals Share Price

2830p 4.0  0.1%

Last Trade - 4:35pm

Large Cap
Market Cap £2.91bn
Enterprise Value £3.14bn
Revenue £481.8m
Position in Universe 236th / 1836
Unlock DPH Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


DPH Revenue Unlock DPH Revenue

Net Income

DPH Net Income Unlock DPH Revenue

Normalised EPS

DPH Normalised EPS Unlock DPH Revenue

PE Ratio Range

DPH PE Ratio Range Unlock DPH Revenue

Dividend Yield Range

DPH Dividend Yield Range Unlock DPH Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
DPH EPS Forecasts Unlock DPH Revenue
Profile Summary

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment includes Dechra Veterinary Products Europe, Dechra Veterinary Products International and Dechra Pharmaceuticals Manufacturing. It manufactures and markets Companion Animal, Equine, Food producing Animal Products and Nutrition. The NA Pharmaceuticals Segment consists of Dechra Veterinary Products US, Putney, Dechra Veterinary Products Canada, and Dechra-Brovel that sell Companion Animal, Equine and Food Producing Animal Products into those territories. The Pharmaceuticals Research and Development Segment includes its pharmaceutical research and development activities. Its offerings include Osphos, Zycortal and Vetoryl.

Last Annual June 30th, 2019
Last Interim June 30th, 2019
Incorporated May 13, 1997
Public Since September 21, 2000
No. of Shareholders: n/a
No. of Employees: 1,731
Sector Healthcare
Industry Pharmaceuticals
Index FTSE All Share , FTSE All Share Health Care , FTSE All Share Pharmaceuticals & Biotechnology , FTSE 350 , FTSE 350 Lower Yield , FTSE 250 , FTSE 350 Pharmaceuticals & Biotechnology , ,
Exchange London Stock Exchange (Full)
Shares in Issue 102,866,886
Free Float (0.0%)
Eligible for
DPH Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for DPH
Upcoming Events for DPH
Monday 24th February, 2020
Half Year 2020 Dechra Pharmaceuticals PLC Earnings Release
Monday 24th February, 2020
Half Year 2020 Dechra Pharmaceuticals PLC Earnings Presentation
Similar to DPH
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.